Skip to main content
NCBI home page
Cancer Immunology, Immunotherapy : CII logoLink to Cancer Immunology, Immunotherapy : CII
. 1994 Nov;39(6):397–400. doi: 10.1007/BF01534427

Clinical pharmacology and tissue disposition studies of131I-labeled anticolorectal carcinoma human monoclonal antibody LiCO 16.88

Michael G Rosenblum 1,✉, Bernard Levin 2, Mark Roh 3, David Hohn 3, Richard McCabe 4, Lora Thompson 1, Lawrence Cheung 1, James L Murray 5
PMCID: PMC11038679  PMID: 8001027

Abstract

Antibody LiCO 16.88 is a human IgM recognizing a 30- to 45-kDa intracytoplasmic antigen present in human adenocarcinoma cells. An 8-mg sample of antibody labeled with 5 mCi131I was co-administered i. v. with 120 mg (three patients), 240 mg (three patients) or 480 mg (four patients) unlabeled antibody as a 4-h infusion. The plasma half-life was 24±1.2 h and the immediate apparent volume of distribution was 5.2±0.2 l at the 28-mg dose level. The plasma half-lives and the cumulative urinary excretion of radiolabel did not seem to vary significantly with increasing doses of unlabeled antibody. However, both the volume of distribution and the clearance rate from plasma increased significantly with increasing antibody dose. Uptake of antibody into tumor tissues obtained during laparotomy 8–9 days after administration varied between 0.00002% ID/g and 0.00127% ID/g. In five of seven patients, the tumor content of antibody was higher than that in adjacent normal tissue. Tumor-to-normal tissue ratios ranged from 0.8 to 10 (Inline graphic=3.8±1.0). In general, the higher radioactivity(cpm)/g tumor was confirmed by both immunoperoxidase and autoradiography. Antibody 16.88 localizes in tumors after administration and may be considered for use in radioimmunotherapy trials.

Key words: Human IgM, Clinical pharmacology, Radiolabeled antibodies

Footnotes

Research conducted, in part, by the Clayton Foundation for Research and supported, in part, by Organon Teknika Inc.

References

  • 1.Waldmann TA. Genetically engineered monoclonal antibodies armed with radionuclides. Year Immunol. 1993;7:205. [PubMed] [Google Scholar]
  • 2.Goldenberg DM. New imaging techniques in gastrointestinal cancer. Curr Opin Oncol. 1993;5:697. doi: 10.1097/00001622-199307000-00014. [DOI] [PubMed] [Google Scholar]
  • 3.McKearn TJ. Radioimmunodetection of solid tumors. Future horizons and applications for radioimmunotherapy. Cancer. 1993;71:4302. doi: 10.1002/1097-0142(19930615)71:12+<4302::aid-cncr2820711820>3.0.co;2-m. [DOI] [PubMed] [Google Scholar]
  • 4.Kuzel TM, Duda RB. The current status of radiolabeled monoclonal antibodies for the diagnosis and treatment of human malignancies. Compr Ther. 1992;18:16. [PubMed] [Google Scholar]
  • 5.Press OW, Eary J, Appelbaum FR, Badger CC, Bernstein ID. Radiolabeled antibody therapy of lymphoma. Cancer Treat Res. 1993;66:127. doi: 10.1007/978-1-4615-3084-8_9. [DOI] [PubMed] [Google Scholar]
  • 6.Scheinberg DA. Monoclonal antibodies in the treatment of myelogenous leukemias. Cancer Treat Res. 1993;64:213. doi: 10.1007/978-1-4615-3086-2_11. [DOI] [PubMed] [Google Scholar]
  • 7.Goldenberg DM. Monoclonal antibodies in cancer detection and therapy. Am J Med. 1993;94:297. doi: 10.1016/0002-9343(93)90062-t. [DOI] [PubMed] [Google Scholar]
  • 8.Stewart JS, Hird V, Snook D, Sullivan M, Hooker G, Courtenay Luck N, Sivolapenko G, Griffiths M, Myers MJ, Lambert HE. Intraperitoneal radioimmunotherapy for ovarian cancer: pharmacokinetics, toxicity, and efficacy of I-131 labeled monoclonal antibodies. Int J Radiat Oncol Biol Phys. 1989;16:405. doi: 10.1016/0360-3016(89)90337-4. [DOI] [PubMed] [Google Scholar]
  • 9.Van Kroonenburgh MJPG, Pauwels EKJ. Human immunological response to mouse monoclonal antibodies in the treatment or diagnosis of malignant diseases. Nucl Med Commun. 1988;9:919. doi: 10.1097/00006231-198811000-00009. [DOI] [PubMed] [Google Scholar]
  • 10.Billetta R, Lobuglio AF. Chimeric antibodies. Int Rev Immunol. 1993;10:165. doi: 10.3109/08830189309061693. [DOI] [PubMed] [Google Scholar]
  • 11.Salch MN, Khazaeli MB, Wheeler RH, Allen L, Tilden AB, Grizzle W, Reisfeld RA, Yu AL, Gillies SD, Lobuglio AF. Phase I trial of the chimeric anti-GD2 monoclonal antibody ch14.18 in patients with malignant melanoma. Hum Antibodies Hybridomas. 1992;3:19. [PubMed] [Google Scholar]
  • 12.Meredith RF, Lobuglio AF, Plott WE, Orr RA, Brezovich IA, Russell CD, Harvey EB, Yester MV, Wagner AJ, Spencer SA. Pharmacokinetics, immune response, and biodistribution of iodine-131-labeled chimeric mouse/human IgG1,k 17-1A monoclonal antibody. J Nucl Med. 1991;32:1162. [PubMed] [Google Scholar]
  • 13.McCabe RP, Peters LC, Haspel MV, Pomato N, Carrasquillo JA, Hanna MG., Jr Preclinical studies on the pharmacokinetic properties of human monoclonal antibodies to colorectal cancer and their use for detection of tumors. Cancer Res. 1988;48:4348. [PubMed] [Google Scholar]
  • 14.Steis RG, Carrasquillo JA, McCabe R, Bookman MA, Reynolds JC, Larson SM, Smith JW, Clark JW, Dailey V, Del Vechio S, et al. Toxicity, immunogenicity, and tumor radioimmunodetecting ability of two human monoclonal antibodies in patients with metastatic colorectal carcinoma. J Clin Oncol. 1990;8:476. doi: 10.1200/JCO.1990.8.3.476. [DOI] [PubMed] [Google Scholar]
  • 15.Khazaeli MB, Saleh MN, Liu T, Kaladas PM, Gilman SC, Lobuglio AF. Frequent anti-V-region immune response to mouse B72.3 monoclonal antibody. J Clin Immunol. 1992;12:116. doi: 10.1007/BF00918141. [DOI] [PubMed] [Google Scholar]
  • 16.Trang JM, Lobuglio AF, Wheeler RH, Harvey EB, Sun L, Ghrayeb J, Khazaeli MB. Pharmacokinetics of a mouse/human chimeric monoclonal antibody (C-17-1A) in metastatic adenocarcinoma patients. Pharm Res. 1990;7:587. doi: 10.1023/a:1015810009701. [DOI] [PubMed] [Google Scholar]
  • 17.LeBerthon B, Khawli LA, Alauddin M, Miller GK, Charak BS, Mazumder A, Epstein AL. Enhanced tumor uptake of macromolecules induced by a novel vasoactive interleukin 2 immunoconjugate. Cancer Res. 1991;51:2694. [PubMed] [Google Scholar]
  • 18.Rosenblum MG, Lamki LM, Murray JL, Carlo DJ, Gutterman JU. Interferon-induced changes in pharmacokinetics and tumor uptake of111In-labeled antimelanoma antibody 96.5 in melanoma patients. J Natl Cancer Inst. 1988;80:160. doi: 10.1093/jnci/80.3.160. [DOI] [PubMed] [Google Scholar]
  • 19.Folli S, Pelegrin A, Chalandon Y, Yao X, Buchegger F, Lienard D, Lejeune F, Mach JP. Tumor-necrosis factor can enhance radio-antibody uptake in human colon carcinoma xenografts by increasing vascular permeability. Int J Cancer. 1993;53:829. doi: 10.1002/ijc.2910530521. [DOI] [PubMed] [Google Scholar]
  • 20.Haisma HJ, Pinedo HM, Kessel MA, van Muijen M, Roos JC, Plaizier MA, Martens HJ, DeJager R, Boven E. Human IgM monoclonal antibody 16.88: pharmacokinetics and immunogenicity in colorectal cancer patients. J Natl Cancer Inst. 1991;83:1813. doi: 10.1093/jnci/83.24.1813. [DOI] [PubMed] [Google Scholar]
  • 21.Haisma HJ, Kessel MA, Silva C, van Muijen M, Roos JC, Bril H, Martens HJ, McCabe R, Boven E. Human IgM monoclonal antibody 16.88: pharmacokinetics and distribution in mouse and man. Br J Cancer. 1990;Suppl 10:40. [PMC free article] [PubMed] [Google Scholar]

Articles from Cancer Immunology, Immunotherapy : CII are provided here courtesy of Springer

RESOURCES